Immunotherapy duo aims to block Melanoma's return in High-Risk patients
NCT ID NCT02656706
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tests whether a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, can prevent melanoma from returning in people who have had surgery to remove stage III or IV melanoma. The treatment is given every few weeks for six months. The main goals are to check for side effects and see how long patients stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital and The Miriam Hospital
Providence, Rhode Island, 02903/02906, United States
Conditions
Explore the condition pages connected to this study.